The glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and now next-generation multi-agonists that include GLP-1 activity, are producing average weight reductions far larger than previously expected from drugs, reshaping clinical practice and how clinicians and patients think about obesity treatment
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of clinical endocrinology and metabolism vol
References Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al
Some researchers explore combining injectable GHK-Cu protocols with microneedling treatments
Dose level matters because most programs price by dose tier